Pacira Pharmaceuticals, Inc. (PCRX) Reports First Quarter EXPAREL Revenue Of $34.4 Million And First Quarter 2014 Results
5/1/2014 2:50:02 PM
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the commercial success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the first quarter ended March 31, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by